Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Olprinone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A known ✓ | Q14432 | 6/20 | 0.98 |
| ▸ | PDE4A known ✓ | P27815 | 2/20 | 0.98 |
| ▸ | PDE3B known ✓ | Q13370 | 5/20 | 0.57 |
| ▸ | PDE5A known ✓ | O76074 | 1/20 | 0.57 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.57 |
| ▸ | PDE4B known ✓ | Q07343 | 1/20 | 0.57 |
| ▸ | PDE4C known ✓ | Q08493 | 1/20 | 0.57 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.57 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.53 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olprinone SCHEMBL6052374 | 1.00 | HPGD (1.00) | HPGDBLMCYP3A4NFKB1PMP22 | |
| Olprinone SCHEMBL27661 | 0.99 | PDE3A (1.00) | HPGDBLMCYP3A4NFKB1PMP22 | |
| Olprinone SCHEMBL19205852 | 0.99 | PDE3A (1.00) | HPGDBLMCYP3A4NFKB1PMP22 | |
| Olprinone SCHEMBL27901698 | 0.98 | PDE3A (0.98) | HPGDBLMCYP3A4NFKB1PMP22 | |
| Olprinone SCHEMBL931814 | 0.94 | PDE3A (0.90) | HPGDBLMCYP3A4NFKB1PMP22 | |
| Olprinone SCHEMBL28068934 | 0.87 | PDE3A (0.77) | HPGDBLMCYP3A4NFKB1PMP22 | |
| SCHEMBL10512080 | 0.84 | PDE3A (0.74) | HPGDBLMCYP3A4NFKB1PMP22 | |
| SCHEMBL10514600 | 0.81 | PDE3A (0.70) | HPGDBLMCYP3A4NFKB1PMP22 | |
| SCHEMBL9460929 | 0.81 | PDE3A (0.70) | HPGDBLMCYP3A4NFKB1PMP22 | |
| SCHEMBL10573731 | 0.81 | PDE3A (0.69) | HPGDBLMCYP3A4NFKB1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 418 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117883374-B | Preparation method of olprinone hydrochloride injection composition | 芜湖杨燕制药有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119080769-A | Method for preparing olprinone hydrochloride | 芜湖御草医药有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-117883374-A | Preparation method of olprinone hydrochloride injection composition | 芜湖杨燕制药有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-220715618-U | Preparation device of olprinone hydrochloride injection | 芜湖杨燕制药有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-115887361-A | Olprinone hydrochloride injection and preparation method thereof | 河北爱尔海泰制药有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-114773341-A | Preparation method of olprinone hydrochloride | 河北爱尔海泰制药有限公司 | 2022-07-22 | — | — | CN | claimed |
| CN-114099426-A | Preparation method of olprinone hydrochloride injection | 芜湖杨燕制药有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-215196363-U | Novel olprinone hydrochloride injection preparation dissolve with stirring device | 山东海雅医药科技有限公司 | 2021-12-17 | — | — | CN | claimed |
| CN-215026624-U | Multi-functional filter membrane filter equipment for olprinone hydrochloride injection | 山东海雅医药科技有限公司 | 2021-12-07 | — | — | CN | claimed |
| CN-111499631-B | Preparation method of olprinone hydrochloride key intermediate 1-imidazo [1,2-a ] pyridin-6-yl-2-acetone | 济南康桥医药科技有限公司 | 2021-07-30 | — | — | CN | claimed |
| CN-108619090-B | High-stability olprinone hydrochloride injection composition | 河北爱尔海泰制药有限公司 | 2020-12-08 | — | — | CN | claimed |
| CN-111499631-A | Preparation method of olprinone hydrochloride key intermediate | 山东美泰医药有限公司 | 2020-08-07 | — | — | CN | claimed |
| US-20080009498-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | NITROMED, INC. (US) | 2008-01-10 | — | — | US | claimed |
| EP-1109543-A4 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2006-03-08 | — | — | EP | claimed |
| US-20040087591-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | GARVEY DAVID S (US) | 2004-05-06 | — | — | US | claimed |
| US-20030023087-A1 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | GARVEY DAVID S (US) | 2003-01-30 | — | — | US | claimed |
| US-20020019405-A1 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | GARVEY DAVID S (US) | 2002-02-14 | — | — | US | claimed |
| EP-1109543-A1 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2001-06-27 | — | — | EP | claimed |
| WO-2000012076-A9 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2000-08-17 | — | — | WO | claimed |
| WO-2000012076-A1 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-03-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023087-A1 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | PDE3A, PDE5A, PTGIS | PDE3A 1/4885PDE4A 17/4885PDE3B 4/4885 |
| US-20020019405-A1 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | PDE3A, PDE5A, PTGIS | PDE3A 1/4885PDE4A 17/4885PDE3B 4/4885 |
| US-20080009498-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | PDE3A, PDE3B, PDE2A | PDE3A 1/4885PDE4A 5/4885PDE3B 2/4885 |
| US-20040087591-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | PDE3A, PDE3B, PDE5A | PDE3A 1/4885PDE4A 10/4885PDE3B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.